Organisation
Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven)
Division
The Lab of Molecular Oncology and Angiogenesis aims to shed light on the genetic and molecular mechanisms that regulate vessel shape remodeling and endothelial cell fate, with the overall aim of defining alternative therapeutic opportunities to improve anti-cancer therapy, as well as therapeutic angiogenesis for revascularization of ischemic tissues.
Current researchers
1 - 7 of 7 results
- Max Mazzone (Responsible)
- Emanuele Berardi (Member)
- Marie-Pauline Orban (Member)
- Carla Riera Domingo (Member)
- Silvia Rivis (Member)
- Tommaso Scolaro (Member)
- Shikang Zhao (Member)
Projects
1 - 10 of 69
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Understanding the roles of the epigenetic machinery in shaping distinct tumor-associated macrophage phenotypes.From10 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
41 - 50 of 311
- Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis(2015)
Authors: Linde De Smedt, Olivier Govaere, Thomas Tousseyn, Eric Van Cutsem, Hans Prenen, Sabine Tejpar, Gert Matthijs, Xavier Sagaert
Pages: 500 - 9 - Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer(2015)
Authors: Eric Van Cutsem, Sabine Tejpar, Hans Prenen
Pages: 1874 - 1881 - PD-030Prospective non-interventional study to collect data on the use of bevacizumab and conventional chemotherapy for the treatment of previously untreated metastatic colorectal cancer in patient's ≥70 years(2016)
Authors: Cindy Kenis, Hans Prenen
Pages: ii113 - ii114 - Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome(2016)
Authors: Geert Maleux, Annouschka Laenen, Chris Verslype, Ignace Vergote, Hans Prenen
Pages: 197 - 203 - Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)(2018)
Authors: Cindy Kenis, Hans Prenen, Eric Van Cutsem, Hans Wildiers
Pages: 93 - 101 - Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer(2016)
Authors: Séverine Vermeire, Hans Prenen
Pages: 127 - 136 - Proteomic analysis of formalin-fixed paraffin-embedded colorectal cancer tissue using tandem mass tag protein labeling(2013)
Authors: Evelyne Maes, Valerie Broeckx, Xavier Sagaert, Bart Landuyt, Hans Prenen, Liliane Schoofs
Pages: 2686 - 2695 - Impact of molecular markers on treatment selection in advanced colorectal cancer(2009)
Authors: Hans Prenen, Sabine Tejpar, Eric Van Cutsem
Pages: 70 - 8 - Gastric cancer(2016)
Authors: Eric Van Cutsem, Xavier Sagaert, Baki Topal, Karin Haustermans, Hans Prenen
Pages: 2654 - 2664 - Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer(2017)
Authors: Cindy Kenis, Hans Prenen, Eric Van Cutsem, Johan Flamaing, Koen Milisen, Hans Wildiers
Pages: E221 - E229